Company Rankings – Amgen Replaces AbbVie in Top Ten Company Ranking
AMGEN REPLACES ABBVIE IN TOP TEN COMPANY RANKING
AbbVie has lost its top ten spot in 2028’s ranking of the largest companies by orphan drug sales. It is replaced by Amgen, whose rare diseases franchise – and ambition – was boosted thanks to the 2023 Horizon Therapeutics acquisition. That deal – bringing Tepezza for thyroid eye disease, Krystexxa for gout and Uplizna for neuromyelitis optica spectrum disorder, plus a pipeline – pushes the Big Biotech into ninth place by forecast 2028 orphan drug sales.
WW Orphan Prescription Drug Sales in 2028: Top 10 Companies
Amgen’s more than $9 billion forecast orphan sales by 2028 represents a 2023-2028 CAGR of more than 17%. Orphan drug sales at Johnson & Johnson and Roche – placed first and second, respectively – will also post double digit CAGR over the next five years. Growth at seventh-placed Pfizer almost hits 10%.
Big Pharma continue to dominate the orphan drug company rankings, though fifth-placed Vertex’s over $12 billion of 2028 orphan drug sales exceed those of Bristol Myers Squibb, Pfizer, Sanofi and Takeda.
Worldwide Orphan Drug Sales (2023/2028): Top 10 Companies
WW Orphan Sales ($bn)
Company
2023
2028
CAGR
1
Johnson & Johnson
16.7
30.6
+12.9%
2
Roche
9.0
16.8
+13.4%
3
AstraZeneca
12.9
16.4
+4.9%
4
Novartis
15.0
13.9
-1.5%
5
Vertex Pharmaceuticals
9.9
12.4
+4.6%
6
Bristol Myers Squibb
16.5
11.3
-7.3%
7
Pfizer
6.9
11.0
+9.8%
8
Sanofi
7.6
10.6
+6.9%
9
Amgen
4.1
9.2
+17.2%
10
Takeda
5.9
7.3
+4.4%
Double digit 2023-2028 orphan sales growth forecast for J&J, Roche and Amgen
